Logo image of VKTX

VIKING THERAPEUTICS INC (VKTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VKTX - US92686J1060 - Common Stock

34.26 USD
-0.01 (-0.03%)
Last: 11/21/2025, 8:04:40 PM
34.2875 USD
+0.03 (+0.08%)
After Hours: 11/21/2025, 8:04:40 PM
Fundamental Rating

3

VKTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 535 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VKTX has reported negative net income.
In the past year VKTX has reported a negative cash flow from operations.
In the past 5 years VKTX always reported negative net income.
In the past 5 years VKTX always reported negative operating cash flow.
VKTX Yearly Net Income VS EBIT VS OCF VS FCFVKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -32.11%, VKTX is in the better half of the industry, outperforming 65.98% of the companies in the same industry.
Looking at the Return On Equity, with a value of -33.29%, VKTX is in the better half of the industry, outperforming 75.14% of the companies in the same industry.
Industry RankSector Rank
ROA -32.11%
ROE -33.29%
ROIC N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
VKTX Yearly ROA, ROE, ROICVKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VKTX Yearly Profit, Operating, Gross MarginsVKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

VKTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VKTX has been increased compared to 5 years ago.
VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VKTX Yearly Shares OutstandingVKTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VKTX Yearly Total Debt VS Total AssetsVKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

VKTX has an Altman-Z score of 86.22. This indicates that VKTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 86.22, VKTX belongs to the top of the industry, outperforming 99.07% of the companies in the same industry.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 86.22
ROIC/WACCN/A
WACCN/A
VKTX Yearly LT Debt VS Equity VS FCFVKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 28.34 indicates that VKTX has no problem at all paying its short term obligations.
The Current ratio of VKTX (28.34) is better than 97.94% of its industry peers.
VKTX has a Quick Ratio of 28.34. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
VKTX's Quick ratio of 28.34 is amongst the best of the industry. VKTX outperforms 97.94% of its industry peers.
Industry RankSector Rank
Current Ratio 28.34
Quick Ratio 28.34
VKTX Yearly Current Assets VS Current LiabilitesVKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

0

3. Growth

3.1 Past

VKTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -127.96%.
EPS 1Y (TTM)-127.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VKTX will show a decrease in Earnings Per Share. The EPS will decrease by -2.37% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-168.74%
EPS Next 2Y-92.2%
EPS Next 3Y-60.22%
EPS Next 5Y-2.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VKTX Yearly Revenue VS EstimatesVKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
VKTX Yearly EPS VS EstimatesVKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.
Also next year VKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VKTX Price Earnings VS Forward Price EarningsVKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VKTX Per share dataVKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

VKTX's earnings are expected to decrease with -60.22% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-92.2%
EPS Next 3Y-60.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VKTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIKING THERAPEUTICS INC

NASDAQ:VKTX (11/21/2025, 8:04:40 PM)

After market: 34.2875 +0.03 (+0.08%)

34.26

-0.01 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-22 2025-10-22/amc
Earnings (Next)02-03 2026-02-03/amc
Inst Owners67.53%
Inst Owner Change-4.94%
Ins Owners2.15%
Ins Owner Change0.68%
Market Cap3.85B
Revenue(TTM)N/A
Net Income(TTM)-237.39M
Analysts86.09
Price Target95.12 (177.64%)
Short Float %22.05%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.29%
Min EPS beat(2)-27.37%
Max EPS beat(2)-17.21%
EPS beat(4)0
Avg EPS beat(4)-20.55%
Min EPS beat(4)-27.37%
Max EPS beat(4)-13.7%
EPS beat(8)4
Avg EPS beat(8)-3.61%
EPS beat(12)5
Avg EPS beat(12)-3.4%
EPS beat(16)7
Avg EPS beat(16)-1.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.73%
PT rev (3m)2.94%
EPS NQ rev (1m)-20.39%
EPS NQ rev (3m)-17.73%
EPS NY rev (1m)-8.77%
EPS NY rev (3m)-9.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.4
P/tB 5.4
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-3.69
Fwd EYN/A
FCF(TTM)-2
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS0
BVpS6.34
TBVpS6.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.11%
ROE -33.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 28.34
Quick Ratio 28.34
Altman-Z 86.22
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-268.18%
EPS Next Y-168.74%
EPS Next 2Y-92.2%
EPS Next 3Y-60.22%
EPS Next 5Y-2.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-105.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-106.94%
EBIT Next 3Y-43.61%
EBIT Next 5Y-22.36%
FCF growth 1Y-236.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-236.85%
OCF growth 3YN/A
OCF growth 5YN/A

VIKING THERAPEUTICS INC / VKTX FAQ

What is the ChartMill fundamental rating of VIKING THERAPEUTICS INC (VKTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VKTX.


What is the valuation status for VKTX stock?

ChartMill assigns a valuation rating of 0 / 10 to VIKING THERAPEUTICS INC (VKTX). This can be considered as Overvalued.


What is the profitability of VKTX stock?

VIKING THERAPEUTICS INC (VKTX) has a profitability rating of 1 / 10.


How financially healthy is VIKING THERAPEUTICS INC?

The financial health rating of VIKING THERAPEUTICS INC (VKTX) is 8 / 10.